111 related articles for article (PubMed ID: 18066809)
1. 2-5A ligands--a new concept for the treatment of prostate cancer.
Cramer H; Okicki JR; Rho T; Wang X; Silverman RH; Heston WD
Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1471-7. PubMed ID: 18066809
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of 2',5'-oligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists.
Wang X; Tian H; Lee Z; Heston WD
Nucleosides Nucleotides Nucleic Acids; 2012 May; 31(5):432-44. PubMed ID: 22497258
[TBL] [Abstract][Full Text] [Related]
3. [Advances in prostate-specific membrane antigen-mediated antitumor drugs].
Lü QZ; Yang JC; Wang YJ
Yao Xue Xue Bao; 2016 Feb; 51(2):234-40. PubMed ID: 29856576
[TBL] [Abstract][Full Text] [Related]
4. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
Liu T; Wu LY; Kazak M; Berkman CE
Prostate; 2008 Jun; 68(9):955-64. PubMed ID: 18361407
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them.
Machulkin AE; Shafikov RR; Uspenskaya AA; Petrov SA; Ber AP; Skvortsov DA; Nimenko EA; Zyk NU; Smirnova GB; Pokrovsky VS; Abakumov MA; Saltykova IV; Akhmirov RT; Garanina AS; Polshakov VI; Saveliev OY; Ivanenkov YA; Aladinskaya AV; Finko AV; Yamansarov EU; Krasnovskaya OO; Erofeev AS; Gorelkin PV; Dontsova OA; Beloglazkina EK; Zyk NV; Khazanova ES; Majouga AG
J Med Chem; 2021 Apr; 64(8):4532-4552. PubMed ID: 33822606
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA.
Ivanenkov YA; Machulkin AE; Garanina AS; Skvortsov DA; Uspenskaya AA; Deyneka EV; Trofimenko AV; Beloglazkina EK; Zyk NV; Koteliansky VE; Bezrukov DS; Aladinskaya AV; Vorobyeva NS; Puchinina MM; Riabykh GK; Sofronova AA; Malyshev AS; Majouga AG
Bioorg Med Chem Lett; 2019 May; 29(10):1246-1255. PubMed ID: 30904185
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Subedi M; Minn I; Chen J; Kim Y; Ok K; Jung YW; Pomper MG; Byun Y
Eur J Med Chem; 2016 Aug; 118():208-218. PubMed ID: 27128184
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells.
Lapidus RG; Tiffany CW; Isaacs JT; Slusher BS
Prostate; 2000 Dec; 45(4):350-4. PubMed ID: 11102961
[TBL] [Abstract][Full Text] [Related]
9. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Santoni M; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Cascinu S; Montironi R
J Biol Regul Homeost Agents; 2014; 28(4):555-63. PubMed ID: 25620167
[TBL] [Abstract][Full Text] [Related]
10. Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.
Vornov JJ; Peters D; Nedelcovych M; Hollinger K; Rais R; Slusher BS
Neurochem Res; 2020 Jun; 45(6):1256-1267. PubMed ID: 31749072
[TBL] [Abstract][Full Text] [Related]
11. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
Hillier SM; Kern AM; Maresca KP; Marquis JC; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2011 Jul; 52(7):1087-93. PubMed ID: 21680691
[TBL] [Abstract][Full Text] [Related]
12. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model.
Yamamoto T; Hirasawa S; Wroblewska B; Grajkowska E; Zhou J; Kozikowski A; Wroblewski J; Neale JH
Eur J Neurosci; 2004 Jul; 20(2):483-94. PubMed ID: 15233757
[TBL] [Abstract][Full Text] [Related]
13. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy.
Schülke N; Varlamova OA; Donovan GP; Ma D; Gardner JP; Morrissey DM; Arrigale RR; Zhan C; Chodera AJ; Surowitz KG; Maddon PJ; Heston WD; Olson WC
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12590-5. PubMed ID: 14583590
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from α-amino acid with (S)- or (R)-configuration at P1' region.
Kwon H; Lim H; Ha H; Choi D; Son SH; Nam H; Minn I; Byun Y
Bioorg Chem; 2020 Nov; 104():104304. PubMed ID: 33011530
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro.
Yao V; Bacich DJ
Prostate; 2006 Jun; 66(8):867-75. PubMed ID: 16496414
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
17. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
18. PSMA-targeted low-molecular double conjugates for diagnostics and therapy.
Petrov SA; Zyk NY; Machulkin AE; Beloglazkina EK; Majouga AG
Eur J Med Chem; 2021 Dec; 225():113752. PubMed ID: 34464875
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
20. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
